Spruce Biosciences, Inc. (SPRB) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 2.50M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 4.59M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 102.85M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $2.50M | $4.59M | (m) | (m) | $102.85M | (m) |
| 2026-03-31 | (m) | (m) | $1.00M | $5.46M | (m) | (m) | $56.17M | (m) |
| 2025-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | (m) | $53.02M | (m) |
| 2025-09-30 | (m) | (m) | $539.00K | $0.00 | (m) | (m) | $15.31M | (m) |
| 2025-06-30 | (m) | (m) | $943.00K | $0.00 | (m) | (m) | $21.82M | (m) |
| 2025-03-31 | (m) | (m) | $1.34M | $0.00 | (m) | (m) | $31.65M | (m) |
| 2024-12-31 | (m) | (m) | $1.62M | $124.00K | (m) | (m) | $45.21M | (m) |
| 2024-09-30 | (m) | (m) | $1.62M | $524.00K | (m) | (m) | $65.10M | (m) |
| 2024-06-30 | (m) | (m) | $1.62M | $923.00K | (m) | (m) | $75.52M | (m) |
| 2024-03-31 | (m) | (m) | $1.62M | $1.32M | (m) | (m) | $87.54M | (m) |
| 2023-12-31 | (m) | (m) | $1.62M | $1.72M | (m) | (m) | $103.95M | (m) |
| 2023-09-30 | (m) | (m) | $1.62M | $2.11M | (m) | (m) | $112.98M | (m) |
| 2023-06-30 | (m) | (m) | $1.62M | $2.51M | (m) | (m) | $125.96M | (m) |
| 2023-03-31 | (m) | (m) | $1.62M | $2.90M | (m) | (m) | $139.11M | (m) |
| 2022-12-31 | (m) | (m) | $1.62M | $3.29M | (m) | (m) | $85.65M | (m) |
| 2022-09-30 | (m) | (m) | $1.22M | $3.69M | (m) | (m) | $95.30M | (m) |
| 2022-06-30 | (m) | (m) | $811.00K | $4.08M | (m) | (m) | $104.52M | (m) |
| 2022-03-31 | (m) | (m) | $405.00K | $4.49M | (m) | (m) | $114.99M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $4.88M | (m) | (m) | $126.49M | (m) |
| 2021-09-30 | (m) | (m) | $0.00 | $4.87M | (m) | (m) | $135.09M | (m) |
| 2021-06-30 | (m) | (m) | $0.00 | $4.86M | (m) | (m) | $143.45M | (m) |
| 2021-03-31 | (m) | (m) | $0.00 | $4.84M | (m) | (m) | $153.99M | (m) |
| 2020-12-31 | (m) | (m) | $2.55M | $1.92M | (m) | (m) | $162.88M | (m) |
| 2020-09-30 | (m) | (m) | $1.91M | $2.56M | (m) | (m) | $78.48M | (m) |
| 2019-12-31 | (m) | (m) | $1.25M | $3.19M | (m) | (m) | $4.69M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |